Sertoli Cell Nanoparticle Delivery for Deep Lung Deposition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pulmonary drug delivery systems face challenges in efficiently delivering drugs to the deep lung, particularly for macromolecules, due to low deposition efficiency, dependency on inhalation technique, and limited payload versatility, which hinders effective treatment of conditions like asthma and COPD.
Innovation Solution
Intravenous injection of Sertoli cells pre-loaded with chitosan nanoparticles, which become entrapped in the lung's pre-capillary vascular bed, allowing for targeted and sustained release of therapeutic compounds like curcumin, optimizing drug delivery to the deep lung.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional aerosol systems are used for pulmonary drug delivery, then the device structure is simple and operation is straightforward, but the deposition efficiency in the deep lung is low (less than 10% of total inhaled dose reaches the deep lung)
Solution Approach 1:
The patent uses surfactants, fatty acids, saccharides, chelating agents, and enzyme inhibitors as intermediary substances to enhance drug permeation and deposition in the deep lung. These agents mediate between the inhaled drug particles and the lung tissue, improving deposition efficiency by facilitating drug penetration through the pulmonary epithelium and reducing clearance mechanisms.
2Reliability
If inhalation therapy is used to deliver macromolecules to the lungs, then the natural bioavailability of deep lung epithelia is maintained, but the efficiency of drug deposition is low and highly dependent on patient inhalation technique
Solution Approach 1:
The patent modifies physical and chemical parameters of the drug delivery system, including particle size optimization (1-3 μm for optimal deposition), formulation composition (adding permeation enhancers like surfactants and fatty acids), and delivery device characteristics. These parameter changes make the delivery system more robust to variations in patient inhalation technique while maintaining reliable deep lung deposition.
3Manufacturing precision
If nanoparticles are delivered through the airway for treatment of asthma and COPD, then the therapeutic effect is achieved, but the delivery efficiency is poor (10-30%) and distribution is difficult to control
Solution Approach 1:
The patent employs permeation enhancers and chelating agents that act locally at the site of drug deposition in the lung. These agents are formulated to concentrate at the airway and alveolar surfaces, enhancing drug penetration and distribution control specifically in the target tissue without affecting other organs, thereby improving both delivery efficiency and distribution control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves high efficiency in delivering 70% of nanoparticles and 80% of curcumin to the lungs, providing a therapeutic effect and improving drug deposition compared to traditional inhalation methods, potentially treating asthma, COPD, and other lung diseases.
Implementation Method 1
Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest... become entrapped in the lung's pre-capillary vascular bed
Implementation Method 2
Sertoli cells pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin
Data Source
AI summary
A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection.